Since its founding in 2005, phenox has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of neurovascular diseases. phenox's products are used by endovascular specialists to treat ischemic and hemorrhagic stroke. The company offers a growing portfolio of innovative treatment options, including the primary interventional technologies used today. The product portfolio comprises the Mechanical Thrombectomy System pRESET, the p64, p48 MW and p64 MW Flow Diverters for the treatment of complex intracranial aneurysms and dissections as well as the pCONUS Implant for the treatment of complex, wide-neck bifurcation aneurysms. The specially developed HPC Technology (Hydrophilic Polymer Coating) for aneurysm treatment products leads to a reduction in the thrombogenicity of the implant surface and thus to an increased patient safety. Since 2020 phenox has also been the exclusive distributor of the Avenir Coiling System developed in California (USA) by Wallaby Medical. In 2022, Wallaby Medical, a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke, announced that it has acquired phenox GmbH, including phenox’s femtos GmbH. This acquisition then lead to rebranding of previously phenox GmbH to WallabyPhenox. Visit our website for further information about phenox and our products: https://www.phenox.net/ Imprint: https://phenox.net/international/imprint/
